Table 1. Correlation between clinicopathological variables and expression of PLA2G16 in 183 cases of breast cancer.
| Variables | Number of patients (%) | PLA2G16 | Pa | |
|---|---|---|---|---|
| Low expression N (%) | High expression N (%) | |||
| Total | 183 | |||
| Age | 0.992 | |||
| ≤50 years | 103 | 54 (29.5) | 49 (26.8) | |
| >50 years | 80 | 42 (23.0) | 38 (20.8) | |
| Menstrual status | 0.132 | |||
| Premenopausal | 113 | 54 (29.5) | 59 (32.2) | |
| Postmenopausal | 70 | 42 (23.0) | 28 (15.3) | |
| Tumor size | 0.066 | |||
| ≤2 cm | 84 | 38 (20.8) | 46 (25.1) | |
| >2, ≤5 cm | 86 | 53 (29.0) | 33 (18.0) | |
| >5 cm | 8 | 2 (1.1) | 6 (3.3) | |
| NA | 5 | 3 (1.6) | 2 (1.1) | |
| Lymph node status | 0.521 | |||
| Negative | 88 | 44 (24.0) | 44 (24.0) | |
| Positive | 95 | 52 (28.4) | 43 (23.5) | |
| Grade | 0.267 | |||
| I | 2 | 1 (0.5) | 1 (0.5) | |
| II | 129 | 63 (34.4) | 66 (36.1) | |
| III | 51 | 32 (17.5) | 19 (10.4) | |
| NA | 1 | 1 (0.0) | 1 (0.5) | |
| ER status | 0.054 | |||
| Negative | 104 | 61 (33.3) | 43 (23.5) | |
| Positive | 79 | 35 (19.1) | 44 (24.0) | |
| PR status | 0.98 | |||
| Negative | 105 | 55 (30.1) | 50 (27.3) | |
| Positive | 78 | 41 (22.4) | 37 (20.2) | |
| HER2 status | 0.698 | |||
| Negative | 88 | 47 (25.8) | 41 (22.5) | |
| Positive | 95 | 49 (26.8) | 46 (25.1) | |
| Subtypeb | 0.369 | |||
| Luminal | 91 | 42 (46.2) | 49 (53.8) | |
| HER-2 Enrichment | 47 | 28 (59.6) | 19 (40.4) | |
| TNBC | 45 | 26 (57.8) | 19 (42.2) | |
a, based on Pearson's χ2 test. b, definition of subtypes: luminal (ER and/or PR positive), HER-2 enrichment (ER and PR negative, HER-2 positive), and TNBC (ER negative, PR negative, and HER-2 negative). ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor receptor 2; PLA2G16, Group XVI phospholipase A2; TNBC, triple negative breast cancer; NA, not available.